These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17647026)

  • 41. Progression of chronic renal disease.
    Klahr S
    Heart Dis; 2001; 3(3):205-9. PubMed ID: 11975793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of TRPC6 ion channels in podocytes - Implications for focal segmental glomerulosclerosis and acquired forms of proteinuric diseases.
    Szabó T; Ambrus L; Zákány N; Balla G; Bíró T
    Acta Physiol Hung; 2015 Sep; 102(3):241-51. PubMed ID: 26551740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
    Slagman MC; Navis G; Laverman GD
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting podocyte-associated diseases.
    Leeuwis JW; Nguyen TQ; Dendooven A; Kok RJ; Goldschmeding R
    Adv Drug Deliv Rev; 2010 Nov; 62(14):1325-36. PubMed ID: 20828590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.
    Epstein M
    J Hypertens; 2001 May; 19(5):829-42. PubMed ID: 11393664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.
    Waanders F; Vaidya VS; van Goor H; Leuvenink H; Damman K; Hamming I; Bonventre JV; Vogt L; Navis G
    Am J Kidney Dis; 2009 Jan; 53(1):16-25. PubMed ID: 18823687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC; Perazella MA
    Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Podocyte loss involves MDM2-driven mitotic catastrophe.
    Mulay SR; Thomasova D; Ryu M; Kulkarni OP; Migliorini A; Bruns H; Gröbmayr R; Lazzeri E; Lasagni L; Liapis H; Romagnani P; Anders HJ
    J Pathol; 2013 Jul; 230(3):322-35. PubMed ID: 23749457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning?
    Abdi R; Brenner BM
    Semin Nephrol; 2004 Mar; 24(2):141-6. PubMed ID: 15017526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential role of mesangial cells and podocytes in TGF-beta-induced mesangial matrix synthesis in chronic glomerular disease.
    Lee HS; Song CY
    Histol Histopathol; 2009 Jul; 24(7):901-8. PubMed ID: 19475536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progression of hypertension and kidney disease in aging fawn-hooded rats is mediated by enhanced influence of renin-angiotensin system and suppression of nitric oxide system and epoxyeicosanoids.
    Doleželová Š; Jíchová Š; Husková Z; Vojtíšková A; Kujal P; Hošková L; Kautzner J; Sadowski J; Červenka L; Kopkan L
    Clin Exp Hypertens; 2016; 38(7):644-651. PubMed ID: 27669111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aldosterone is a major factor in the progression of renal disease.
    Ibrahim HN; Rosenberg ME; Greene EL; Kren S; Hostetter TH
    Kidney Int Suppl; 1997 Dec; 63():S115-9. PubMed ID: 9407437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic measures in proteinuric nephropathy.
    Praga M
    Kidney Int Suppl; 2005 Dec; (99):S137-41. PubMed ID: 16336567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic kidney disease: effects on the cardiovascular system.
    Schiffrin EL; Lipman ML; Mann JF
    Circulation; 2007 Jul; 116(1):85-97. PubMed ID: 17606856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease.
    Sonneveld R; Ferrè S; Hoenderop JG; Dijkman HB; Berden JH; Bindels RJ; Wetzels JF; van der Vlag J; Nijenhuis T
    Am J Pathol; 2013 Apr; 182(4):1196-204. PubMed ID: 23385000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of RAS/Wnt/β-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy.
    Chen L; Chen DQ; Wang M; Liu D; Chen H; Dou F; Vaziri ND; Zhao YY
    Chem Biol Interact; 2017 Aug; 273():56-72. PubMed ID: 28578904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease.
    Tian X; Ishibe S
    Nephrol Dial Transplant; 2016 Oct; 31(10):1577-83. PubMed ID: 26968197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vitamin D in chronic kidney disease: new potential for intervention.
    Mirković K; van den Born J; Navis G; de Borst MH
    Curr Drug Targets; 2011 Jan; 12(1):42-53. PubMed ID: 20795938
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
    Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.